Livongo priced its shares above their range to raise more than $355m, providing exits to Merck GHI, M12, Humana, Zaffre Investments and Echo Health Ventures.

Livongo Health, a US-based health management technology developer backed by corporates including pharmaceutical firm Merck & Co and care provider Humana, went public yesterday in an initial public offering sized at more than $355m. The IPO consisted of approximately 12.7 million shares priced at $28 each, signficantly above the $20 to $23 range it had…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.